TWI763668B - 整合應激途徑之調節劑 - Google Patents

整合應激途徑之調節劑

Info

Publication number
TWI763668B
TWI763668B TW106114859A TW106114859A TWI763668B TW I763668 B TWI763668 B TW I763668B TW 106114859 A TW106114859 A TW 106114859A TW 106114859 A TW106114859 A TW 106114859A TW I763668 B TWI763668 B TW I763668B
Authority
TW
Taiwan
Prior art keywords
alkyl
formula
disease
compound
independently
Prior art date
Application number
TW106114859A
Other languages
English (en)
Chinese (zh)
Other versions
TW201808887A (zh
Inventor
卡美拉 希卓斯基
馬瑞那 普利烏希奇福
珍妮佛 Ｍ 佛斯特
勞倫斯 A 布雷克
向東 徐
瑞姆茲 法拉 史威斯
雷 施
慶偉 張
芸頌 童
查爾斯 Ｗ 修欽斯
勝元 鍾
麥克 Ｊ 達特
Original Assignee
美商嘉來克生命科學有限責任公司
美商艾伯維有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商嘉來克生命科學有限責任公司, 美商艾伯維有限公司 filed Critical 美商嘉來克生命科學有限責任公司
Publication of TW201808887A publication Critical patent/TW201808887A/zh
Application granted granted Critical
Publication of TWI763668B publication Critical patent/TWI763668B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/23—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/24—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/38—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing five carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/40—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/44—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing eight carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/90—Ring systems containing bridged rings containing more than four rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
TW106114859A 2016-05-05 2017-05-04 整合應激途徑之調節劑 TWI763668B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662332278P 2016-05-05 2016-05-05
US62/332,278 2016-05-05

Publications (2)

Publication Number Publication Date
TW201808887A TW201808887A (zh) 2018-03-16
TWI763668B true TWI763668B (zh) 2022-05-11

Family

ID=58709639

Family Applications (2)

Application Number Title Priority Date Filing Date
TW106114859A TWI763668B (zh) 2016-05-05 2017-05-04 整合應激途徑之調節劑
TW111113522A TWI844006B (zh) 2016-05-05 2017-05-04 整合應激途徑之調節劑

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW111113522A TWI844006B (zh) 2016-05-05 2017-05-04 整合應激途徑之調節劑

Country Status (38)

Country Link
US (3) US20190144440A1 (enExample)
EP (2) EP4356971A3 (enExample)
JP (4) JP6997766B2 (enExample)
KR (3) KR20250042188A (enExample)
CN (2) CN115947681B (enExample)
AR (1) AR110599A1 (enExample)
AU (3) AU2017260367B2 (enExample)
BR (1) BR112018072663A2 (enExample)
CA (1) CA3023162A1 (enExample)
CL (1) CL2018003142A1 (enExample)
CO (1) CO2018012946A2 (enExample)
CR (2) CR20180574A (enExample)
DK (1) DK3452448T3 (enExample)
DO (1) DOP2018000242A (enExample)
EC (1) ECSP18089579A (enExample)
ES (1) ES2973442T3 (enExample)
FI (1) FI3452448T3 (enExample)
HR (1) HRP20240218T1 (enExample)
HU (1) HUE065713T2 (enExample)
IL (3) IL286693B2 (enExample)
LT (1) LT3452448T (enExample)
MA (1) MA44861B1 (enExample)
MD (1) MD3452448T2 (enExample)
MX (2) MX383652B (enExample)
MY (1) MY200943A (enExample)
PE (2) PE20231935A1 (enExample)
PH (1) PH12018502329B1 (enExample)
PL (1) PL3452448T3 (enExample)
PT (1) PT3452448T (enExample)
RS (1) RS65214B1 (enExample)
RU (2) RU2022106770A (enExample)
SG (1) SG11201809695TA (enExample)
SI (1) SI3452448T1 (enExample)
SM (1) SMT202400098T1 (enExample)
TW (2) TWI763668B (enExample)
UA (1) UA125513C2 (enExample)
UY (2) UY40873A (enExample)
WO (1) WO2017193034A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI920577B (zh) 2016-05-05 2026-04-01 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3634952A1 (en) * 2017-06-07 2020-04-15 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
CA3068753A1 (en) * 2017-07-03 2019-01-10 Glaxosmithkline Intellectual Property Development Limited N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-cyclobutane-1-carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
CR20200054A (es) 2017-08-09 2020-03-21 Denali Therapeutics Inc Compuestos, composiciones y métodos
HUE062446T2 (hu) 2017-09-01 2023-11-28 Denali Therapeutics Inc Vegyületek, készítmények és eljárások
UY37958A (es) * 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
JP2021501785A (ja) 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
UY37956A (es) * 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
AU2018383675A1 (en) 2017-12-13 2020-07-09 Altos Labs, Inc. Inhibitors of integrated stress response pathway
EP3768660A1 (en) * 2018-03-23 2021-01-27 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2
MX2020013269A (es) 2018-06-05 2021-02-18 Praxis Biotech LLC Inhibidores de la vía de respuesta al estrés integrada.
EP3820843A1 (en) * 2018-07-09 2021-05-19 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds
TWI771621B (zh) * 2018-10-11 2022-07-21 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑
MA54959A (fr) 2019-02-13 2021-12-22 Denali Therapeutics Inc Composés, compositions et procédés
EP3923935A4 (en) 2019-02-13 2022-10-26 Denali Therapeutics Inc. COMPOUNDS, COMPOSITIONS AND METHODS
CN113840597A (zh) * 2019-02-25 2021-12-24 普拉西斯生物技术有限责任公司 整合应激反应通路抑制剂
IL287379B2 (en) 2019-04-23 2025-11-01 Evotec Int Gmbh Modulators of the integrated stress response pathway
CA3137212A1 (en) 2019-04-23 2020-10-29 Evotec International Gmbh Modulators of the integrated stress response pathway
PE20220572A1 (es) * 2019-04-30 2022-04-20 Calico Life Sciences Llc Moduladores de la via integrada del estres
EP3962899A1 (en) * 2019-04-30 2022-03-09 Calico Life Sciences LLC Substituted cyclolakyls as modulators of the integrated stress pathway
CN114466654A (zh) 2019-06-12 2022-05-10 普拉西斯生物技术有限责任公司 整合应激反应通路调节剂
MX2022006865A (es) * 2019-12-06 2022-07-11 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
EP4096665A1 (en) 2020-01-28 2022-12-07 Evotec International GmbH Modulators of the integrated stress response pathway
CA3165813A1 (en) 2020-03-11 2021-09-16 Holly Victoria Atton Modulators of the integrated stress response pathway
WO2022013684A1 (en) 2020-07-11 2022-01-20 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
MX2023004626A (es) 2020-10-22 2023-05-23 Evotec Int Gmbh Moduladores de la via de respuesta integrada al estres.
KR20230110509A (ko) 2020-10-22 2023-07-24 에보텍 인터내셔널 게엠베하 통합 스트레스 반응 경로의 조절제
AU2021363616B2 (en) 2020-10-22 2026-03-26 Evotec International Gmbh Modulators of the integrated stress response pathway
US20220184034A1 (en) * 2020-12-10 2022-06-16 Adgero Biopharmaceuticals Holdings, Inc. Methods for treating cutaneous metastatic cancers
KR20250122004A (ko) * 2024-02-05 2025-08-13 재단법인 대구경북첨단의료산업진흥재단 신규한 eIF2B 작용제 및 이를 포함하는 대사질환 예방 또는 치료용 조성물
WO2025255324A1 (en) * 2024-06-06 2025-12-11 Lapis Therapeutics, Inc. Inhibitors of lipoprotein(a) assembly

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070185079A1 (en) * 2004-01-07 2007-08-09 Astrazeneca Ab Therapeutic agents I
WO2014144952A2 (en) * 2013-03-15 2014-09-18 Peter Walter Modulators of the eif2alpha pathway

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212A (en) 1847-07-31 Richard m
US162A (en) 1837-04-17 Island
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
GB0400196D0 (en) * 2004-01-07 2004-02-11 Astrazeneca Ab Therapeutic agents
WO2006012395A2 (en) * 2004-07-23 2006-02-02 Susan Marie Royalty Peptidase inhibitors
EP1924553A1 (en) * 2005-08-08 2008-05-28 Argenta Discovery Limited Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
GB0516314D0 (en) * 2005-08-08 2005-09-14 Argenta Discovery Ltd Compound
CA2618103A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
US20110201818A1 (en) * 2007-09-25 2011-08-18 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
WO2011116161A2 (en) * 2010-03-17 2011-09-22 Axikin Pharmaceuticals Inc. Arylsulfonamide ccr3 antagonists
EP2604601B1 (en) * 2010-08-10 2016-02-24 Astellas Pharma Inc. Hetero ring compound
AR084457A1 (es) * 2010-12-22 2013-05-15 Lundbeck & Co As H Derivados de biciclo[3,2,1]octilamida
US20160318856A1 (en) * 2013-09-11 2016-11-03 The Brigham And Women's Hospital, Inc. Substituted Urea eIF2alpha Kinase Activators
RU2016141934A (ru) * 2014-04-04 2018-05-07 Сирос Фармасьютикалз, Инк. Ингибиторы циклин-зависимой киназы 7 (cdk7)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070185079A1 (en) * 2004-01-07 2007-08-09 Astrazeneca Ab Therapeutic agents I
WO2014144952A2 (en) * 2013-03-15 2014-09-18 Peter Walter Modulators of the eif2alpha pathway

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI920577B (zh) 2016-05-05 2026-04-01 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑

Also Published As

Publication number Publication date
PL3452448T3 (pl) 2024-07-08
TWI844006B (zh) 2024-06-01
BR112018072663A2 (pt) 2019-02-19
CN109641844B (zh) 2022-11-01
PT3452448T (pt) 2024-03-19
WO2017193034A1 (en) 2017-11-09
RU2022106770A (ru) 2022-04-05
PH12018502329B1 (en) 2023-08-11
EP3452448B1 (en) 2023-12-20
ECSP18089579A (es) 2019-02-28
MA44861A (fr) 2019-03-13
CR20180574A (es) 2019-05-15
AU2017260367A1 (en) 2018-11-22
MY200943A (en) 2024-01-24
RU2018142740A3 (enExample) 2020-08-24
JP2022046578A (ja) 2022-03-23
CR20210372A (es) 2022-06-07
NZ787908A (en) 2025-05-30
CN115947681A (zh) 2023-04-11
EP4356971A3 (en) 2024-07-24
FI3452448T3 (fi) 2024-03-19
AU2024227527A1 (en) 2024-11-14
CA3023162A1 (en) 2017-11-09
PE20231935A1 (es) 2023-12-05
RS65214B1 (sr) 2024-03-29
IL262722B (en) 2021-10-31
JP2019515043A (ja) 2019-06-06
RU2018142740A (ru) 2020-06-05
KR102781404B1 (ko) 2025-03-18
AU2017260367B2 (en) 2021-12-02
UY37228A (es) 2017-11-30
SMT202400098T1 (it) 2024-05-14
KR102512049B1 (ko) 2023-03-21
EP4356971A2 (en) 2024-04-24
US20190144440A1 (en) 2019-05-16
TW201808887A (zh) 2018-03-16
RU2769327C2 (ru) 2022-03-30
MA44861B1 (fr) 2024-02-29
IL286693A (en) 2021-10-31
CO2018012946A2 (es) 2019-08-20
ES2973442T3 (es) 2024-06-20
MX383652B (es) 2025-03-14
UA125513C2 (uk) 2022-04-13
IL286693B1 (en) 2025-11-01
CN109641844A (zh) 2019-04-16
DOP2018000242A (es) 2019-04-15
IL323840A (en) 2025-12-01
PH12018502329A1 (en) 2019-03-25
LT3452448T (lt) 2024-03-12
NZ747842A (en) 2025-05-30
IL262722A (en) 2018-12-31
US20220363678A1 (en) 2022-11-17
MD3452448T2 (ro) 2024-04-30
HRP20240218T1 (hr) 2024-04-26
IL286693B2 (en) 2026-03-01
SI3452448T1 (sl) 2024-04-30
US20250122188A1 (en) 2025-04-17
CN115947681B (zh) 2025-10-14
CL2018003142A1 (es) 2019-05-24
JP2026009986A (ja) 2026-01-21
SG11201809695TA (en) 2018-11-29
JP7755632B2 (ja) 2025-10-16
JP7389786B2 (ja) 2023-11-30
MX2018013495A (es) 2019-07-04
TW202304851A (zh) 2023-02-01
DK3452448T3 (da) 2024-02-12
KR20190031203A (ko) 2019-03-25
EP3452448A1 (en) 2019-03-13
AU2022200946A1 (en) 2022-03-03
TW202506629A (zh) 2025-02-16
KR20230042146A (ko) 2023-03-27
AR110599A1 (es) 2019-04-17
JP2024023324A (ja) 2024-02-21
HUE065713T2 (hu) 2024-06-28
UY40873A (es) 2024-09-13
MX2021007146A (es) 2022-11-29
PE20190348A1 (es) 2019-03-07
AU2022200946B2 (en) 2024-07-25
KR20250042188A (ko) 2025-03-26
JP6997766B2 (ja) 2022-01-20

Similar Documents

Publication Publication Date Title
JP7755632B2 (ja) 統合的ストレス経路のモジュレーター
AU2023201821B2 (en) Modulators of the integrated stress pathway
CN112204009B (zh) 整合应激通路的调节剂
CN109641854B (zh) 整合应激通路的调节剂
TWI920577B (zh) 整合應激途徑之調節劑
HK40110222A (en) Modulators of the integrated stress pathway
HK40044910B (zh) 整合应激通路的调节剂
HK40044136A (en) Modulators of the integrated stress pathway
HK40044911B (zh) 整合应激通路的调节剂